HDAC2 promotes cell migration/invasion abilities through HIF-1α stabilization in human oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 40, Issue 7, 2011, Pages 567-575

  Chang, Cheng Chi ^a   Lin, Been Ren ^b   Chen, Szu Ta ^b   Hsieh, Tsung Han ^a   Li, Yue Ju ^c   Kuo, Mark Y P ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Histone deacetylase 2; Hypoxia inducible factor 1 ; Invasion; Migration; Oral cancer

Indexed keywords

HISTONE DEACETYLASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SHORT HAIRPIN RNA; TRANSCRIPTOME; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR MECHANICS; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; SQUAMOUS CELL CARCINOMA; STABLE EXPRESSION; UBIQUITINATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE 2; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHATIC METASTASIS; LYSINE; MICE; MICE, SCID; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; RANDOM ALLOCATION; UBIQUITINATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 79960629010     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2011.01009.x     Document Type: Article

References (30)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328: 184-94.
2. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143-54.
3. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-92.
4. Luger K. Structure and dynamic behavior of nucleosomes. Curr Opin Genet Dev 2003; 13: 127-35.
5. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-5.
6. Gregory PD, Wagner K, Horz W. Histone acetylation and chromatin remodeling. Exp Cell Res 2001; 265: 195-202.
7. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70: 81-120.
8. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001; 262: 75-83.
9. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003; 983: 84-100.
10. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84.
11. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004; 73: 417-35.
12. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15-23.
13. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17-31.
14. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
15. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet 2003; 19: 286-93.
16. Bruick RK. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev 2003; 17: 2614-23.
17. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998; 12: 149-62.
18. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88: 1474-80.
19. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-8.
20. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-72.
21. Brahimi-Horn C, Mazure N, Pouyssegur J. Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal 2005; 17: 1-9.
22. Jeong JW, Bae MK, Ahn MY, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002; 111: 709-20.
23. Chang CC, Lin MT, Lin BR, et al. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. J Natl Cancer Inst 2006; 98: 984-95.
24. Fath DM, Kong X, Liang D, et al. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J Biol Chem 2006; 281: 13612-9.
25. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2006; 26: 2019-28.
26. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001; 7: 437-43.
27. Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009; 280: 145-53.
28. Chang HH, Chiang CP, Hung HC, Lin CY, Deng YT, Kuo MY. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 2009; 45: 610-4.
29. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
30. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-68.